

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		09830992
	Filing Date		2001-05-03
	First Named Inventor	Lubisch	
	Art Unit	1626	
	Examiner Name	Stockton, Laura L.	
	Attorney Docket Number	0050/049500USO1	

### U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	4093726	A	1978-06-06	Winn et al.	
	2	6372736	B1	2002-04-16	Kemp et al.	
	3	6696437	B1	2004-02-24	Lubisch et al.	
	4	7462724	B2	2008-12-09	Penning et al.	
	5	7550603	B1	2008-06-23	Zhu et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

### U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20030100582	A1	2003-05-29	Sircar et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09830992
Filing Date	2001-05-03
First Named Inventor	Lubisch
Art Unit	1626
Examiner Name	Stockton, Laura L.
Attorney Docket Number	0050/049500USO1

2	20060229351	A1	2006-10-12	Zhu et al.	
3	20070179136	A1	2007-08-02	Penning et al.	
4	20070265324	A1	2007-11-15	Werner et al.	
5	20090186877	A1	2009-03-30	Giranda et al.	
6	20090030016	A1	2008-07-15	Gandhi et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

**FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	3830060	DE	A1	1990-03-15	Boehringer Mannheim GmbH		<input checked="" type="checkbox"/>
	2	19916460	DE	A1	2000-10-19	BASF AG		<input checked="" type="checkbox"/>
	3	19920936	DE	A1	2001-11-09	BASF AG		<input type="checkbox"/>
	4	10021468	DE	A1	2001-11-08	BASF AG		<input checked="" type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09830992
Filing Date	2001-05-03
First Named Inventor	Lubisch
Art Unit	1626
Examiner Name	Stockton, Laura L.
Attorney Docket Number	0050/049500USO1

5	1354554	GB	A	1974-06-05	Robins Co Inc		<input type="checkbox"/>
6	97/04771	WO	A1	1997-02-13	Univ Newcastle Ventures LTD		<input type="checkbox"/>
7	98/39343	WO	A1	1998-09-11	Metabasis Therapeutics Inc		<input type="checkbox"/>
8	00/26192	WO	A1	2000-05-11	BASF AG		<input type="checkbox"/>
9	00/29384	WO	A1	2000-05-25	BASF AG		<input type="checkbox"/>
10	00/32579	WO	A1	2000-06-08	BASF AG		<input type="checkbox"/>
11	01/21615	WO	A1	2001-03-29	Yamanouchi Pharma Co Ltd		<input checked="" type="checkbox"/>
12	01/21634	WO	A1	2001-03-29	Trega Biosciences		<input type="checkbox"/>
13	01/82877	WO	A2	2001-11-08	BASF AG		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
--------------------	---------	---	----------------

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09830992
Filing Date	2001-05-03
First Named Inventor	Lubisch
Art Unit	1626
Examiner Name	Stockton, Laura L.
Attorney Docket Number	0050/049500USO1

1	Gilchrist, et al., "Cyclisation of ortho-Substituted N-Arylben zimidoyl Nitrenes. Part 2. Preferential Cyclisations at an ortho-Position Bearin a Methoxycarbonyl Group", Journal of Chem. Society, Perkin Transactions 1, GB, Chemical Society, Letchworth, 2303-2307 (1979)	<input type="checkbox"/>
2	Griffin, et al., "Resistance modifying agents 3. Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase." Pharmaceutical Sciences, 2(1), 43-47 (1996)	<input type="checkbox"/>
3	Kröger, H., et al., "Synergistic Effects of Thalidomide and Poly(ADP-Ribose) Polymerase Inhibition of Type II Collagen-Induced Arthritis in Mice", Inflammation, 20(2):203-215 (1996)	<input type="checkbox"/>
4	Burkart, V., et al., "Mice lacking the poly (ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin", Nat. Med., 5(3):314-319 (1999)	<input type="checkbox"/>
5	Chen, et al., "Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide", Cancer Chem. Pharm., 22:303-307 (1988)	<input type="checkbox"/>
6	Cuzzocrea, S., et al., "Protective effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthase in a carrageenan-induced model of local inflammation", Eur. J. of Pharm., 342:67-76 (1998)	<input type="checkbox"/>
7	Ehrlich, W., et al., "Inhibition of the induction of collagenase by interleukin-1 $\alpha$ in cultured rabbit synovial fibroblasts after treatment with the poly(ADP-ribose)-polymerase inhibitor 3-aminobenzamide", Rheumatol Int., 15:171-172 (1995)	<input type="checkbox"/>
8	Szabo, C., et al., "Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase", Proc. Natl. Acad. Sci. USA, 95:3867-3872 (1998)	<input type="checkbox"/>
9	Thiemermann, C., et al., "Inhibition of the activity of poly (ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle", Proc. Natl. Acad. Sci. USA, 94:679-683 (1997)	<input type="checkbox"/>
10	Weltin, D., et al., "Immunosuppressive Activities of 6(5H)-Phenanthridinone, A New Poly(ADP-Ribose)Polymerase Inhibitor", Int. J. Immunopharmac., 17(4):265-271 (1995)	<input type="checkbox"/>
11	White, A.W., et al. "Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitor", Bioorganic & Medicinal Chemistry Letters, 2004, 14:2433-2437 (2004)	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		09830992
Filing Date		2001-05-03
First Named Inventor	Lubisch	
Art Unit	1626	
Examiner Name	Stockton, Laura L.	
Attorney Docket Number	0050/049500USO1	

12	Co-pending Application U.S. Patent Application No. 11/401,635	<input type="checkbox"/>
13	Co-pending Application U.S. Patent Application No. 12/413,834	<input type="checkbox"/>
14	Co-pending Application U.S. Patent Application No. 11/623,996	<input type="checkbox"/>
15	Co-pending Application U.S. Patent Application No. 11/970,828	<input type="checkbox"/>
16	Co-pending Application U.S. Patent Application No. 12/058,478	<input type="checkbox"/>
17	Co-pending Application U.S. Patent Application No. 12/116,823	<input type="checkbox"/>
18	Co-pending Application U.S. Patent Application No. 12/117,452	<input type="checkbox"/>
19	Co-pending Application U.S. Patent Application No. 12/173,213	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.